CO6300848A2 - Composiciones farmacéuticas que comprenden péptidos con mif (factor de migración de inhibición de macrofagos) - Google Patents
Composiciones farmacéuticas que comprenden péptidos con mif (factor de migración de inhibición de macrofagos)Info
- Publication number
- CO6300848A2 CO6300848A2 CO10116141A CO10116141A CO6300848A2 CO 6300848 A2 CO6300848 A2 CO 6300848A2 CO 10116141 A CO10116141 A CO 10116141A CO 10116141 A CO10116141 A CO 10116141A CO 6300848 A2 CO6300848 A2 CO 6300848A2
- Authority
- CO
- Colombia
- Prior art keywords
- mif
- cancer
- macrofagus
- pharmaceutical compositions
- include peptides
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 230000005764 inhibitory process Effects 0.000 title 1
- 230000005012 migration Effects 0.000 title 1
- 238000013508 migration Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 abstract 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 abstract 2
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 abstract 2
- 108010018951 Interleukin-8B Receptors Proteins 0.000 abstract 2
- 208000002223 abdominal aortic aneurysm Diseases 0.000 abstract 2
- 208000007474 aortic aneurysm Diseases 0.000 abstract 2
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 abstract 1
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 208000035539 Ovarian infection Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 206010035664 Pneumonia Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 206010063837 Reperfusion injury Diseases 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 208000029742 colonic neoplasm Diseases 0.000 abstract 1
- 201000003146 cystitis Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 208000031225 myocardial ischemia Diseases 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Vascular Medicine (AREA)
- Biochemistry (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3838108P | 2008-03-20 | 2008-03-20 | |
| US3937108P | 2008-03-25 | 2008-03-25 | |
| US4580708P | 2008-04-17 | 2008-04-17 | |
| US12109508P | 2008-12-09 | 2008-12-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6300848A2 true CO6300848A2 (es) | 2011-07-21 |
Family
ID=41091567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO10116141A CO6300848A2 (es) | 2008-03-20 | 2010-09-20 | Composiciones farmacéuticas que comprenden péptidos con mif (factor de migración de inhibición de macrofagos) |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20110044988A1 (OSRAM) |
| EP (2) | EP2252318A4 (OSRAM) |
| JP (2) | JP2011526244A (OSRAM) |
| KR (1) | KR20110014141A (OSRAM) |
| CN (2) | CN102046199A (OSRAM) |
| AU (2) | AU2009225389A1 (OSRAM) |
| BR (1) | BRPI0910259A2 (OSRAM) |
| CA (2) | CA2717365A1 (OSRAM) |
| CO (1) | CO6300848A2 (OSRAM) |
| EA (1) | EA201001529A1 (OSRAM) |
| IL (1) | IL207752A0 (OSRAM) |
| MX (1) | MX2010010198A (OSRAM) |
| NZ (1) | NZ588033A (OSRAM) |
| WO (2) | WO2009117706A2 (OSRAM) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009117706A2 (en) * | 2008-03-20 | 2009-09-24 | Carolus Therapeutics, Inc. | Methods of treatment using anti-mif antibodies |
| WO2009120186A1 (en) * | 2008-03-24 | 2009-10-01 | Carolus Therapeutics, Inc. | Methods and compositions for treating atherosclerosis and related conditions |
| US20100183598A1 (en) * | 2008-11-12 | 2010-07-22 | Carolus Therapeutics, Inc. | Methods of treating cardiovascular disorders |
| WO2011038149A2 (en) * | 2009-09-23 | 2011-03-31 | Carolus Therapeutics, Inc. | Methods of treating inflammation |
| EP2308484A1 (en) | 2009-10-06 | 2011-04-13 | Dompé S.p.a. | Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets |
| EP2308485A1 (en) * | 2009-10-06 | 2011-04-13 | Dompé S.p.a. | Sulfonamides for the prevention of diabetes |
| WO2012125680A1 (en) | 2011-03-16 | 2012-09-20 | Novartis Ag | Methods of treating vasculitis using an il-17 binding molecule |
| EP2696682B1 (en) * | 2011-04-13 | 2018-03-21 | Innovimmune Biotherapeutics, Inc. | Mif inhibitors and their uses |
| TWI407964B (zh) * | 2011-05-10 | 2013-09-11 | Univ Fu Jen Catholic | 干擾性核糖核酸用於治療或減緩疼痛之用途 |
| EP2723380B1 (en) | 2011-06-24 | 2019-08-21 | Stephen D. Gillies | Light chain immunoglobulin fusion proteins and methods of use thereof |
| US10596233B2 (en) | 2011-06-30 | 2020-03-24 | Dignity Health | Use of pertussis toxin as a therapeutic agent |
| WO2013003786A1 (en) * | 2011-06-30 | 2013-01-03 | Dignity Health | Use of pertussis toxin as a therapeutic agent |
| EP2731970B1 (en) | 2011-07-15 | 2018-11-28 | MorphoSys AG | Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt) |
| CN102357249A (zh) * | 2011-10-26 | 2012-02-22 | 广州赫尔氏药物开发有限公司 | 能够抑制耐药性结核杆菌的药物 |
| DK2844250T3 (en) | 2012-05-01 | 2018-01-08 | Translatum Medicus Inc | METHODS OF TREATMENT AND DIAGNOSTICATION OF EYE DISEASES CONCERNING BLINDNESS |
| US10561676B2 (en) * | 2013-08-02 | 2020-02-18 | Syntrix Biosystems Inc. | Method for treating cancer using dual antagonists of CXCR1 and CXCR2 |
| US10046002B2 (en) | 2013-08-02 | 2018-08-14 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
| US10316075B2 (en) | 2013-10-03 | 2019-06-11 | Oregon Health & Science University | Recombinant polypeptides comprising MHC class II α1 domains |
| EP3242685B1 (en) | 2015-01-09 | 2022-05-04 | AdAlta Limited | Cxcr4 binding molecules |
| TW201718851A (zh) * | 2015-09-18 | 2017-06-01 | 通用醫院公司 | 具有抗化學排斥(anti-fugetactic)性質之經修飾自然殺手細胞及其用途 |
| CA3008279A1 (en) | 2015-12-14 | 2017-06-22 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| CA3008272A1 (en) * | 2015-12-14 | 2017-06-22 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| BR112018068393A2 (pt) | 2016-03-11 | 2019-01-15 | Ardea Biosciences Inc | inibidores de cxcr-2 para o tratamento de distúrbios de artropatia por cristais |
| KR102645432B1 (ko) * | 2016-03-28 | 2024-03-11 | (주)아모레퍼시픽 | 피부 세포 분화 촉진용 조성물 및 피부 세포 분화 촉진 물질의 스크리닝 방법 |
| JP2019510785A (ja) | 2016-04-08 | 2019-04-18 | エックス４ ファーマシューティカルズ， インコーポレイテッド | 癌を処置する方法 |
| EP3445402A4 (en) * | 2016-04-21 | 2019-12-11 | The Board Of Regents Of The University Of Texas System | METHOD AND COMPOSITIONS FOR DETECTING ANEURYSMS |
| JP7461741B2 (ja) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン |
| CA3027498A1 (en) | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
| US10988465B2 (en) | 2016-06-21 | 2021-04-27 | X4 Pharmaceuticals, Inc. | CXCR4 inhibitors and uses thereof |
| WO2017223243A1 (en) | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
| CN109890364B (zh) | 2016-10-03 | 2023-10-17 | 儿童医疗中心公司 | 糖尿病肾病的预防和治疗 |
| CN108355133A (zh) * | 2017-01-26 | 2018-08-03 | 中国医学科学院阜外医院 | 靶向cxcr7的药物组合物和方法 |
| WO2019084313A1 (en) * | 2017-10-27 | 2019-05-02 | Board Of Regents, The University Of Texas System | USE OF SDHA AS PROGNOSTIC MARKER AND THERAPEUTIC TARGET FOR UREAL MELANOMA |
| CN107964045B (zh) * | 2017-12-18 | 2021-04-23 | 南京医科大学 | 一种人鼠嵌合抗CXCR2全分子IgG及其应用 |
| KR20210009315A (ko) | 2018-04-11 | 2021-01-26 | 오하이오 스테이트 이노베이션 파운데이션 | 안약 전달용 서방형 마이크로 입자를 이용한 방법 및 조성물 |
| US11679146B2 (en) | 2018-06-05 | 2023-06-20 | Anji Pharmaceuticals Inc. | Compositions and methods for treating pancreatitis |
| JP2021526820A (ja) * | 2018-06-07 | 2021-10-11 | オンコワン・リサーチ・アンド・ディベロップメント・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 癌治療のための抗ｏｘＭＩＦ／抗ＣＤ３抗体 |
| US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
| EP3884277A1 (en) * | 2018-12-26 | 2021-09-29 | Colgate-Palmolive Company | Biomarkers of neutrophil deregulation as diagnostic for gingivitis |
| CN110133306B (zh) * | 2019-05-09 | 2023-04-07 | 北京勤邦生物技术有限公司 | 检测西马特罗的酶联免疫试剂盒及其应用 |
| EP4117662A4 (en) | 2020-03-10 | 2024-04-03 | X4 Pharmaceuticals, Inc. | METHODS OF TREATING NEUTROPENIA |
| MX2022011231A (es) * | 2020-03-11 | 2022-11-07 | Biolinerx Ltd | Inhibidor de cxcr4 para el tratamiento del sindrome de dificultad respiratoria aguda e infecciones virales. |
| WO2021219495A1 (en) * | 2020-04-28 | 2021-11-04 | Dalcor Pharma Uk Ltd., Leatherhead, Zug Branch | Methods for treating or preventing a viral infection or inhibiting viral replication |
| CA3196362A1 (en) * | 2020-10-28 | 2022-05-05 | University Health Network (Uhn) | Methods of treating spondyloarthritis or symptoms thereof |
| KR102866709B1 (ko) * | 2021-03-22 | 2025-10-02 | 클립스비엔씨 주식회사 | 신규한 재조합 마이코박테리움 스메그마티스 균주 및 이의 용도 |
| EP4320445A1 (en) | 2021-04-08 | 2024-02-14 | Joslin Diabetes Center, Inc. | Methods of diagnosing and predicting renal decline |
| KR102561554B1 (ko) * | 2021-04-14 | 2023-07-28 | 부산대학교 산학협력단 | 치주질환 진단용 바이오마커 조성물, 치주질환 치료 효용성 평가용 바이오마커 조성물 및 이를 이용한 진단키트 |
| EP4472735A2 (en) * | 2022-02-04 | 2024-12-11 | University of Pittsburgh - of the Commonwealth System of Higher Education | Methods of detecting and treating cerebral aneurysms |
| WO2025171411A1 (en) * | 2024-02-09 | 2025-08-14 | Herophilus, Inc. | Compositions and methods related to modulating macrophage migration inhibitory factor (mif)-cd74 signaling and related treatments for neuroinflammatory conditions |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994026307A1 (en) * | 1993-05-17 | 1994-11-24 | The Picower Institute For Medical Research | Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity |
| US6030615A (en) * | 1993-05-17 | 2000-02-29 | The Picower Institute For Medical Research | Combination method for treating diseases caused by cytokine-mediated toxicity |
| US20070072861A1 (en) * | 2000-03-27 | 2007-03-29 | Barbara Roniker | Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders |
| CA2434671A1 (en) * | 2001-01-12 | 2002-09-06 | The Picower Institute For Medical Research | Methods and compositions for modulating regulation of the cytotoxic lymphocyte response by macrophage migration inhibitory factor |
| JP2003226653A (ja) * | 2001-11-30 | 2003-08-12 | Jun Nishihira | 多発性硬化症治療剤 |
| WO2003047622A1 (fr) * | 2001-11-30 | 2003-06-12 | Jun Nishihira | Remedes pour la sclerose en plaques |
| US6656168B2 (en) * | 2001-12-18 | 2003-12-02 | Kimberly-Clark Worldwide, Inc. | Feminine care product with discrete areas of a skin wellness additive |
| US20040009149A1 (en) * | 2002-02-27 | 2004-01-15 | Altman John D. | Multimeric binding complexes |
| JP4472351B2 (ja) * | 2002-03-01 | 2010-06-02 | イミューノメディクス、インコーポレイテッド | インターナライジング抗ｃｄ７４抗体およびその使用方法 |
| ES2364155T3 (es) * | 2002-11-25 | 2011-08-25 | Jallal Messadek | Composiciones de betaína y ácido acetilsalicílico. |
| TW200418829A (en) * | 2003-02-14 | 2004-10-01 | Avanir Pharmaceutics | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| US20050202010A1 (en) * | 2003-08-29 | 2005-09-15 | Giroir Brett P. | Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor |
| WO2005065328A2 (en) * | 2003-12-30 | 2005-07-21 | The United States Of America, As Represented By The Department Of Veterans Affairs | Macrophage migration inhibitory factor (mif) as marker for urological inflammatory disease |
| WO2006105666A1 (en) * | 2005-04-06 | 2006-10-12 | Queen's University At Kingston | Administration of macrophage targeted formulations of compounds which modulate cholesterol-metabolizing enzymes for treatment of atherosclerosis |
| US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| WO2007138961A1 (ja) * | 2006-05-29 | 2007-12-06 | Redox Bioscience Inc. | マクロファージ遊走阻止因子によって引き起こされる障害の予防乃至治療剤 |
| WO2009117706A2 (en) * | 2008-03-20 | 2009-09-24 | Carolus Therapeutics, Inc. | Methods of treatment using anti-mif antibodies |
| WO2009120186A1 (en) * | 2008-03-24 | 2009-10-01 | Carolus Therapeutics, Inc. | Methods and compositions for treating atherosclerosis and related conditions |
| US20100183598A1 (en) * | 2008-11-12 | 2010-07-22 | Carolus Therapeutics, Inc. | Methods of treating cardiovascular disorders |
| WO2010065491A2 (en) * | 2008-12-01 | 2010-06-10 | Carolus Therapeutics, Inc. | Methods of treating inflammatory disorders |
-
2009
- 2009-03-20 WO PCT/US2009/037883 patent/WO2009117706A2/en not_active Ceased
- 2009-03-20 CN CN200980109905XA patent/CN102046199A/zh active Pending
- 2009-03-20 EA EA201001529A patent/EA201001529A1/ru unknown
- 2009-03-20 AU AU2009225389A patent/AU2009225389A1/en not_active Abandoned
- 2009-03-20 MX MX2010010198A patent/MX2010010198A/es active IP Right Grant
- 2009-03-20 WO PCT/US2009/037887 patent/WO2009117710A2/en not_active Ceased
- 2009-03-20 KR KR1020107023480A patent/KR20110014141A/ko not_active Withdrawn
- 2009-03-20 US US12/918,968 patent/US20110044988A1/en not_active Abandoned
- 2009-03-20 CA CA2717365A patent/CA2717365A1/en not_active Abandoned
- 2009-03-20 EP EP09721240A patent/EP2252318A4/en not_active Withdrawn
- 2009-03-20 EP EP09722541A patent/EP2254597A4/en not_active Withdrawn
- 2009-03-20 AU AU2009225385A patent/AU2009225385A1/en not_active Abandoned
- 2009-03-20 JP JP2011501003A patent/JP2011526244A/ja active Pending
- 2009-03-20 JP JP2011501000A patent/JP2011515416A/ja active Pending
- 2009-03-20 CN CN2009801093284A patent/CN102088993A/zh active Pending
- 2009-03-20 US US12/918,964 patent/US20110262386A1/en not_active Abandoned
- 2009-03-20 BR BRPI0910259A patent/BRPI0910259A2/pt not_active IP Right Cessation
- 2009-03-20 NZ NZ588033A patent/NZ588033A/xx not_active IP Right Cessation
- 2009-03-20 CA CA2717071A patent/CA2717071A1/en not_active Abandoned
-
2010
- 2010-08-23 IL IL207752A patent/IL207752A0/en unknown
- 2010-09-20 CO CO10116141A patent/CO6300848A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011515416A (ja) | 2011-05-19 |
| US20110044988A1 (en) | 2011-02-24 |
| WO2009117706A3 (en) | 2010-01-21 |
| AU2009225385A1 (en) | 2009-09-24 |
| EP2252318A2 (en) | 2010-11-24 |
| KR20110014141A (ko) | 2011-02-10 |
| WO2009117710A3 (en) | 2010-01-21 |
| CN102046199A (zh) | 2011-05-04 |
| WO2009117706A2 (en) | 2009-09-24 |
| WO2009117710A2 (en) | 2009-09-24 |
| EP2254597A2 (en) | 2010-12-01 |
| CA2717071A1 (en) | 2009-09-24 |
| CA2717365A1 (en) | 2009-09-24 |
| EA201001529A1 (ru) | 2011-06-30 |
| EP2254597A4 (en) | 2012-04-18 |
| AU2009225389A1 (en) | 2009-09-24 |
| IL207752A0 (en) | 2010-12-30 |
| CN102088993A (zh) | 2011-06-08 |
| MX2010010198A (es) | 2010-12-21 |
| BRPI0910259A2 (pt) | 2015-12-01 |
| EP2252318A4 (en) | 2012-04-18 |
| JP2011526244A (ja) | 2011-10-06 |
| NZ588033A (en) | 2012-11-30 |
| US20110262386A1 (en) | 2011-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6300848A2 (es) | Composiciones farmacéuticas que comprenden péptidos con mif (factor de migración de inhibición de macrofagos) | |
| GT201700067A (es) | Compuestos de aminopiridiloxipirazol | |
| CY1123126T1 (el) | Συνθεσεις για την αγωγη γαστρεντερικης φλεγμονης | |
| MX2009012968A (es) | Polipeptidos, dominios variables de anticuerpo y antagonistas. | |
| EA200901300A1 (ru) | Полипептиды, вариабельные домены антител и антагонисты | |
| UA103882C2 (uk) | Композиція пухлино-асоційованих пептидів та відповідна протиракова вакцина | |
| CY1119979T1 (el) | Φαρμακευτικες συνθεσεις που περιεχουν τοξοειδη α και β toy clostridium difficile | |
| ECSP10010288A (es) | Vectores de virus oncolíticos de viruela | |
| CL2012001298A1 (es) | Compuestos derivados del acido carbomoil-metilamino acetico sustituido, inhibidores de nep; composicion farmaceutica; combinacion farmaceutica; y uso para el tratamiento de hipertension arterial, hipertension pulmonar, insuficiencia cardiaca, entre otras. | |
| CL2008001593A1 (es) | Compuestos derivados de heterociclos, antagonistas para el ccr2; y uso de los compuestos para tratar afecciones o enfermedades del tracto respiratorio, como enfermedad pulmonar obstructiva cronica y asma. | |
| CL2008001047A1 (es) | Compuestos derivados de difenil-dihidro-imidazopiridinonas; inhibidores de mdm2-p53;composicion farmaceutica;y uso para preparar un medicamento destinado al tratamiento o control de tumores solidos,tales como:tumores de mama.de colon,de pulmon o de prostata. | |
| UY30794A1 (es) | Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinic0 | |
| ECSP10010287A (es) | Vectores de virus oncolíticos de viruela | |
| BRPI0908637B8 (pt) | composto e composição farmacêutica do mesmo | |
| EA201491819A1 (ru) | Фармацевтические композиции для комбинированного лечения | |
| CL2008001898A1 (es) | Compuestos derivados de pirazinona, inhibidores de p38; proceso de preparacion de estos; composicion farmaceutica que los comprende; combinacion farmaceutica que los comprende; uso para tratar enferemedades pulmonares obstructivas cronicas y asma. | |
| CL2007003774A1 (es) | Compuestos derivados de quinazolina sustituidos, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, aterosclerosis y artritis. | |
| EA201070549A1 (ru) | Жидкие композиции lh | |
| BR112015003751A2 (pt) | conjugados da anticorpo-droga (adc) que se ligam a proteínas 158p1d7 | |
| ECSP099341A (es) | Nuevos anticuerpos antiproliferativos | |
| JP2015505843A5 (OSRAM) | ||
| MX336339B (es) | Nuevo uso antitumoral de cabazitaxel. | |
| EA201171074A1 (ru) | Цитотоксические конъюгаты с соединением, связывающим рецептор нейропептида y | |
| CO6612185A2 (es) | Composiciones famacéuticas para el tratamiento del cáncer y otras enfermedades o transtornos | |
| AR099068A1 (es) | Anticuerpo anti-netrina-1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |